P1‐363: MONITORING THE SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA (SAPPA) AND BETA (SAPPB) FRAGMENTS IN PLASMA AND CSF FROM HEALTHY INDIVIDUALS TREATED WITH BACE INHIBITOR AZD3293 IN A MULTIPLE ASCENDING DOSE STUDY: PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATE

Subjects Completing Month 12, n (%) 28(77.8) 27(73) 30(83.3) 29(78.4) Male, n (%) 13(36.1) 18(48.6) 19(52.8) 12(32.4) Mean Age (SD) 73.3(8.79) 73.5(8.34) 74.1(9.26) 70.5(8.68) ApoE *e4 Carriers, n (%) 22(61.1) 22(59.5) 22(61.1) 22(59.5) Symptomatic AD Treatment 29(80.6) 30(81.1) 34(94.4) 30(81.1) Mean Florbetapir PET GCA SUVR (SD) 1.74(0.294) 1.75(0.313) 1.87(0.299) 1.85(0.316) Mean MMSE Total Score (SD) 22.3(2.84) 22.3(2.78) 21.5(2.47) 21.9(2.99) Mean ADAS-Cog/11 Total Score (SD) 18.3(6.70) 19.6(9.47) 20.9(7.66) 18.4(8.34) Mean DAD Total Score (SD) 86.5(15.31) 81.7(17.41) 86.1(12.92) 85.2(13.25) Florbetapir PET GCA SUVR Change From Baseline at Month 12 Within-treatment LS Mean 0.000 -0.014 -0.066 -0.021 (95% CI) (-0.062, .063) (-0.078, .050) (-0.129, -0.004) (-0.084, 0.004) p-value 0.991 0.661 0.038 0.492 Florbetapir PET GCA SUVR Change From Baseline at Month 12 Between-treatment Difference of LS Means -0.015 -0.067 -0.022 (95% CI) (-0.103, 0.074) (-0.155, 0.022) (-0.109, 0.066) p-value 0.747 0.138 0.627 Poster Presentations: P1 P447